Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1998 Apr;168(4):272–274.

Combination therapy with an angiotensin converting enzyme inhibitor and an angiotensin-II receptor antagonist for refractory essential hypertension.

J D Bisognano 1, L D Horwitz 1
PMCID: PMC1304961  PMID: 9584674

Full text

PDF
272

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azizi M., Chatellier G., Guyene T. T., Murieta-Geoffroy D., Ménard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation. 1995 Aug 15;92(4):825–834. doi: 10.1161/01.cir.92.4.825. [DOI] [PubMed] [Google Scholar]
  2. Ding Y. A., Chang S. M., Chou T. C. Comparison of amlodipine and quinapril on ambulatory blood pressure and platelet function in hypertension. J Hum Hypertens. 1995 Aug;9(8):637–641. [PubMed] [Google Scholar]
  3. Goodfriend T. L., Elliott M. E., Catt K. J. Angiotensin receptors and their antagonists. N Engl J Med. 1996 Jun 20;334(25):1649–1654. doi: 10.1056/NEJM199606203342507. [DOI] [PubMed] [Google Scholar]
  4. Lessem J. N., Rucinska E., Vickers F. F., Espie J., Sromovsky J. A. Long-term enalapril--a new converting enzyme inhibitor--in the treatment of mild to moderate essential hypertension, results of a worldwide multiclinic study. Comparing two ways of analyzing data. Clin Exp Hypertens A. 1985;7(11):1515–1539. doi: 10.3109/10641968509073607. [DOI] [PubMed] [Google Scholar]
  5. Liao Y., Husain A. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases. Can J Cardiol. 1995 Aug;11 (Suppl F):13F–19F. [PubMed] [Google Scholar]
  6. Nunez E., Hosoya K., Susic D., Frohlich E. D. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension. 1997 Jan;29(1 Pt 2):519–524. doi: 10.1161/01.hyp.29.1.519. [DOI] [PubMed] [Google Scholar]
  7. Okunishi H., Miyazaki M., Okamura T., Toda N. Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem Biophys Res Commun. 1987 Dec 31;149(3):1186–1192. doi: 10.1016/0006-291x(87)90533-x. [DOI] [PubMed] [Google Scholar]
  8. Plosker G. L., Sorkin E. M. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders. Drugs. 1994 Aug;48(2):227–252. doi: 10.2165/00003495-199448020-00008. [DOI] [PubMed] [Google Scholar]
  9. Urata H., Healy B., Stewart R. W., Bumpus F. M., Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990 Apr;66(4):883–890. doi: 10.1161/01.res.66.4.883. [DOI] [PubMed] [Google Scholar]
  10. Zisman L. S., Abraham W. T., Meixell G. E., Vamvakias B. N., Quaife R. A., Lowes B. D., Roden R. L., Peacock S. J., Groves B. M., Raynolds M. V. Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway. J Clin Invest. 1995 Sep;96(3):1490–1498. doi: 10.1172/JCI118186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. van den Meiracker A. H., Man in 't Veld A. J., Admiraal P. J., Ritsema van Eck H. J., Boomsma F., Derkx F. H., Schalekamp M. A. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens. 1992 Aug;10(8):803–812. [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES